Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

An Eli Lilly spokesperson told Pharmaceutical Technology: “[The telehealth companies] are deceptively marketing knockoff tirzepatide as safe and effective for ‘cosmetic weight loss ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. Its latest push continues that effort but also goes a step further, inviting ...

Eli Lilly (LLY-3.41%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, including with its GLP-1 medications.

Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...